Uterine Fibroids – Pipeline Review, H1 2013

Publisher Name :
Date: 28-Mar-2013
No. of pages: 67
Inquire Before Buying

Summary

Global Markets Direct’s, ‘Uterine Fibroids – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Uterine Fibroids, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Fibroids. Uterine Fibroids – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Uterine Fibroids.
  • A review of the Uterine Fibroids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Uterine Fibroids pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Uterine Fibroids.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Uterine Fibroids pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Uterine Fibroids – Pipeline Review, H1 2013

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Uterine Fibroids Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Uterine Fibroids 8
Uterine Fibroids Therapeutics under Development by Companies 10
Uterine Fibroids Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Uterine Fibroids Therapeutics - Products under Development by Companies 17
Uterine Fibroids Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Uterine Fibroids Therapeutics Development 19
Takeda Pharmaceutical Company Limited 19
Neurocrine Biosciences, Inc. 20
Kissei Pharmaceutical Co., Ltd. 21
Bayer AG 22
Repros Therapeutics Inc. 23
HRA Pharma, SA 24
Tokai Pharmaceuticals, Inc. 25
Uterine Fibroids - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
TAK-385 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
telapristone acetate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ulipristal acetate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ulipristal acetate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
mifepristone - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
KLH-2109 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BAY-1002670 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GnRH Antagonists - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Non-Steroidal Progesterone Agonist - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Uterine Fibroids Therapeutics - Drug Profile Updates 43
Uterine Fibroids Therapeutics - Discontinued Products 53
Uterine Fibroids Therapeutics - Dormant Products 54
Uterine Fibroids - Product Development Milestones 55
Featured News & Press Releases 55
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 55
Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 55
Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 56
Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 57
Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 58
Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 59
Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 61
Jan 03, 2012: Repros Completes Dosing In Phase II Low-Dose Oral Proellex Trial 62
Dec 16, 2011: PregLem Receives Positive EMA/CHMP Opinion For Esmya For Pre-Operative Treatment Of Uterine Fibroids 63
Dec 15, 2011: CHMP Recommends Granting Of Marketing Authorization For Esmya 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables

Number of Products Under Development for Uterine Fibroids, H1 2013 8
Products under Development for Uterine Fibroids - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 18
Takeda Pharmaceutical Company Limited, H1 2013 19
Neurocrine Biosciences, Inc., H1 2013 20
Kissei Pharmaceutical Co., Ltd., H1 2013 21
Bayer AG, H1 2013 22
Repros Therapeutics Inc., H1 2013 23
HRA Pharma, SA, H1 2013 24
Tokai Pharmaceuticals, Inc., H1 2013 25
Assessment by Monotherapy Products, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 30
Uterine Fibroids Therapeutics - Drug Profile Updates 43
Uterine Fibroids Therapeutics - Discontinued Products 53
Uterine Fibroids Therapeutics - Dormant Products 54

List of Figures

Number of Products under Development for Uterine Fibroids, H1 2013 8
Products under Development for Uterine Fibroids - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Discovery and Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 26
Assessment by Route of Administration, H1 2013 27
Assessment by Stage and Route of Administration, H1 2013 28
Assessment by Molecule Type, H1 2013 29
Assessment by Stage and Molecule Type, H1 2013 30

  • Increase in Surgical Procedures Propelling the Anesthesia Drugs Market
    With increase in surgical operations and invasive medical tests, the market for anesthesia drugs has been growing at a steady pace. Anesthesia drugs can be broadly categorized into two types – general anesthesia drugs and local anesthesia drugs. Anesthetic drugs help in inducing sleep and preventing discomfort and pain during surgical procedures. By 2018, the [...]
  • Water Treatment Chemicals Market to be driven by Increasing Demand from Developing Economies
    The global market for water treatment chemicals is growing at a steady pace with rapid urbanization and high demand from end-users. Water treatment chemicals are used for treating municipal water as well as agricultural wastewater. With higher demand for clean, drinking water with increasing population and increase in the number of industries, the global market [...]
  • Rise in Prevalence of Allergic Diseases Driving the Global Allergy Diagnostics Market
    With rise in the incidences of allergic diseases in the world, the global allergy diagnostics market has also witnessed steady growth. In recent years, there has been an increase in the number of people suffering from different allergies, particularly food allergies and drug allergies. The number of people suffering from asthma has also increased in [...]
  • Global Video Surveillance Market Driven by Increasing Demand for Security
    The global market for video surveillance has been witnessing steady growth with increase in demand for advanced surveillance systems by different law enforcement agencies. Increase in adoption of video surveillance by different sectors such as banking and finance, healthcare, transportation, and retail is one of the major drivers in the market. In 2013, the global [...]
  • Global Empty Capsules Market Driven by Growth in Pharmaceutical Industry
    With rapid growth in the pharmaceutical industry, the market for empty capsules has also grown at a steady pace. Some of the factors which are driving the growth of the empty capsules market are rise in aging population which is increasing the demand for capsule based drugs, technological advancement and increase in demand from the [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • OpportunityAnalyzer: Acromegaly and Gigantism – Opportunity Analysis and Forecast to 2018
    Published: 18-Dec-2014        Price: US $7995 Onwards        Pages: 161
    GlobalData estimates the 2013 sales for acromegaly and gigantism at approximately $588m across the 6MM covered in this report. The market will grow moderately at a CAGR of 3.74% during the five year forecast period, generating sales of approximately $707m at the end of 2018. Growing at a CAGR of 4.58% and generating around 68% of global sales in 2018, the US market will experience twice the rate of growth of the 5EU market. Two major trends are visible among the pipeline drugs and research and d......
  • Russia: Eyeglasses (Optics) Market. Analysis and Forecast to 2017
    Published: 18-Dec-2014        Price: US $3281 Onwards        Pages: 257
    The report provides current information about the Russian Optical Glasses Market as of January 2012 The objectives of this market research report are to describe the state of the Russian sunglasses and eyeglasses (optics) market and to provide current information on volumes of production, exports, imports, consumption and market conditions, changes that occurred in 2010 and 2011, As well as to build a forecast of the industry in the medium term for the period before 2017 The optics market ......
  • 2014 Market Research Report on Global Disposable Syringe Industry
    Published: 17-Dec-2014        Price: US $2600 Onwards        Pages: 178
    This is a professional and depth research report on Global Disposable Syringe industry For overview analysis, the report introduces Disposable Syringe basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc For international and China market analysis, the report analyzes Disposable Syringe markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research o......
  • 2014 Market Research Report on Global Vitamin K3 Industry
    Published: 17-Dec-2014        Price: US $2600 Onwards        Pages: 180
    This is a professional and depth research report on Global Vitamin K3 industry For overview analysis, the report introduces Vitamin K3 basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc For international and China market analysis, the report analyzes Vitamin K3 markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of dif......
  • Kazakhstan Pharmaceuticals and Healthcare Report Q1 2015
    Published: 17-Dec-2014        Price: US $1295 Onwards        Pages: 95
    BMI View: Plans to boost government spending on healthcare will be positive for the pharmaceutical industry as well as other participants in the healthcare sector. Over the longer term, the introduction of compulsory health insurance will create a large pool of funding for further growth. However, a key risk to our outlook is oil prices and their effect on Kazakh government revenues. Headline Expenditure Projections ? Pharmaceuticals: KZT273.92bn (USD1.80bn) in 2013 to KZT335.18bn (USD1.84bn) in......
  • Global Male Infertility Market 2015-2019
    Published: 17-Dec-2014        Price: US $2500 Onwards        Pages: 71
    Infertility is a widespread problem. In male infertility, the male fails to impregnate his female partner after a year of unprotected sex. Male infertility is due to a couple of factors including: Low sperm production Abnormal sperm function or Blockages that prevent the delivery of sperm. Hormonal disturbances to physical problems, or psychological problems can cause male infertility. In most cases, there are no obvious sign or symptoms of an infertility problem. 20 percent of the to......
  • Philippines Pharmaceuticals and Healthcare Report Q1 2015
    Published: 17-Dec-2014        Price: US $1295 Onwards        Pages: 129
    BMI View: Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing population and high burden of disease profile. Generic medicines will continue to account for an increasing share of pharmaceutical sales in the Philippines, galvanised by expanding government provision of healthcare as well as improvements in generic drug distribution. This provides strong growth opportunities for generic drug manufacturers in an emerging market where economic growth will b......
  • Global Cystic Fibrosis Market 2015-2019
    Published: 17-Dec-2014        Price: US $3000 Onwards        Pages: 125
    Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country. Cystic fibrosis is a chronic disease. The production of a high-salt containing sweat and s......
  • United Kingdom Pharmaceuticals and Healthcare Report Q1 2015
    Published: 17-Dec-2014        Price: US $1295 Onwards        Pages: 130
    BMI View: The pharmaceutical and healthcare markets of the United Kingdom are driven by government spending in the form of the National Health System (NHS), which accounts for over 80% of total healthcare spending. With a higher prevalence of non-communicable diseases, coupled with an ageing population, the increased demand for healthcare may lead to the enforcement of cost-containment strategies and movement away from expensive treatment options. Headline Expenditure Projections Pharmaceuticals......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs